Drug Trial News

RSS

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers

11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.

11 Apr 2013

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.

10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.

9 Apr 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals, Inc. today announced the presentation of preclinical data on ponatinib (Iclusig) , at the American Association for Cancer Research Annual Meeting 2013, in Washington.

9 Apr 2013

Clinical data of two Transgene products to be presented at EASL Conference

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).

9 Apr 2013

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.

8 Apr 2013

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

8 Apr 2013

Drug Trial News

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Data on PV-10 combination therapy presented at AACR Annual Meeting

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Researchers evaluate Pexa-Vec to slow progression of liver cancer

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

REVEAL trial: VASCAZEN meets primary endpoint

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

Clinical data of two Transgene products to be presented at EASL Conference

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News